keyword
https://read.qxmd.com/read/38641785/evaluating-a-web-based-training-curriculum-for-disseminating-best-practices-for-the-care-of-newborns-with-neonatal-opioid-withdrawal-syndrome-in-a-rural-hospital-the-nows-nm-program
#1
JOURNAL ARTICLE
Heather Pratt-Chavez, Heidi Rishel Brakey, Sarah G Sanders, Juhee Patel, Tim Ozechowski, Chloe Stoffel, Andrew L Sussman, Jessie Marquez, David R Smith, Alberta S Kong
BACKGROUND: The incidence of neonatal opiate withdrawal syndrome (NOWS) in the US has grown dramatically over the past two decades. Many rural hospitals not equipped to manage these patients transfer them to hospitals in bigger cities. METHODS: We created a curriculum, the NOWS-NM Program, a web-based curriculum training in best practices. To evaluate the curriculum, we conducted pre- and post-surveys of NOWS knowledge, attitudes, and care practices, plus post-curriculum interviews and focus groups...
April 19, 2024: BMC Pediatrics
https://read.qxmd.com/read/38570361/unveiling-the-link-between-chronic-pain-and-misuse-of-opioids-and-cannabis
#2
REVIEW
Merel Dagher, Myra Alayoubi, Gabriella H Sigal, Catherine M Cahill
Over 50 million Americans endure chronic pain where many do not receive adequate treatment and self-medicate to manage their pain by taking substances like opioids and cannabis. Research has shown high comorbidity between chronic pain and substance use disorders (SUD) and these disorders share many common neurobiological underpinnings, including hypodopaminergic transmission. Drugs commonly used for self-medication such as opioids and cannabis relieve emotional, bothersome components of pain as well as negative emotional affect that perpetuates misuse and increases the risk of progressing towards drug abuse...
April 3, 2024: Journal of Neural Transmission
https://read.qxmd.com/read/38558723/methadone-withdrawal-induced-psychosis-a-case-report
#3
Oluwaseun Oke, Marta B Sekh, Bamidele O Johnson, Samuel Adeyemo
Methadone is a synthetic full µ-opioid receptor agonist and N-methyl-D-aspartate antagonist given to patients who have recently stopped using illicit opioids or are tapering off chronic opioid pain medication. Maintenance treatment with methadone is today the most widespread and effective way to treat opiate addiction, which achieves abstinence, decreases morbidity and mortality, improves quality of life, and reduces crime genesis, among other benefits. It is also approved by the Food and Drug Administration for treating moderate-to-severe pain that remains unresponsive to nonopioid medications...
February 2024: Curēus
https://read.qxmd.com/read/38556414/precipitated-opioid-withdrawal-in-a-patient-started-on-olanzapine-samidorphan
#4
Andrew Chambers, Jessica Patton, Brandon K Wills
BACKGROUND: Olanzapine/Samidorphan (Lybalvi®) is a novel oral agent for the treatment of schizophrenia and bipolar I disorder. It was designed to reduce weight gain associated with olanzapine. Samidorphan is an analog of naltrexone, initially intended to treat substance use disorders by antagonizing mu, delta, and kappa opioid receptors. CASE REPORT: We present the case of a 36-year-old who took their first dose of olanzapine/samidorphan shortly before calling for emergency services...
March 26, 2024: American Journal of Emergency Medicine
https://read.qxmd.com/read/38533719/tianeptine-as-an-opiate-replacement-in-a-patient-on-methadone-treatment-a-case-report
#5
JOURNAL ARTICLE
Vivek Velagapudi, Jordan Calabrese, Roopa Sethi
Tianeptine, an antidepressant and full µ-opioid receptor agonist, has increased in popularity and has been used as an over-the-counter supplement over the past decade. Due to its well-documented euphoric effects, there exists elevated risk for potential abuse. Buprenorphine-naloxone has been successfully utilized to treat opioid use disorder (OUD) in patients concurrently using tianeptine, limiting withdrawal symptoms and abstinence. However, there is limited evidence on the management of tianeptine use disorder, specifically methadone or naltrexone...
2024: Journal of Opioid Management
https://read.qxmd.com/read/38518270/psychedelic-therapy-a-primer-for-primary-care-clinicians-ibogaine
#6
JOURNAL ARTICLE
Kirsten Cherian, Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Bryce D Beutler, Viviana D Evans, Chelsey Fasano, Owen S Muir
BACKGROUND: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder, depression, anxiety, and traumatic brain injury. AREAS OF UNCERTAINTY: Ibogaine requires careful patient screening and monitoring because of significant safety issues...
March 2024: American Journal of Therapeutics
https://read.qxmd.com/read/38502911/withdrawal-catastrophizing-scale-initial-psychometric-properties-and-implications-for-the-study-of-opioid-use-disorder-and-hyperkatifeia
#7
JOURNAL ARTICLE
Orman Trent Hall, Michael Vilensky, Julie E Teater, Craig Bryan, Kara Rood, Julie Niedermier, Parker Entrup, Stephanie Gorka, Anthony King, David A Williams, K Luan Phan
Background: Discovery of modifiable factors influencing subjective withdrawal experience might advance opioid use disorder (OUD) research and precision treatment. This study explores one factor - withdrawal catastrophizing - a negative cognitive and emotional orientation toward withdrawal characterized by excessive fear, worry or inability to divert attention from withdrawal symptoms. Objectives: We define a novel concept - withdrawal catastrophizing - and present an initial evaluation of the Withdrawal Catastrophizing Scale (WCS)...
March 19, 2024: American Journal of Drug and Alcohol Abuse
https://read.qxmd.com/read/38502432/effect-of-oral-naloxone-on-opioid-induced-constipation-in-methadone-maintenance-treatment-patients-a-double-blind-placebo-control-clinical-trial
#8
JOURNAL ARTICLE
Shaghayegh Akhgarandouz, Mohammad Moshiri, Leila Etemad, Bita Dadpour, Majid Khadem-Rezaiyan, Nasser Vahdati-Mashhadian
BACKGROUND: Opioid-induced constipation (OIC) is the most prevalent side effect of methadone maintenance therapy (MMT). Naloxone could reduce the OIC. METHOD: Fifty-six MMT cases (< 75 mg/day methadone, > 3 months) were entered randomly into four groups of a trial. They received placebo or naloxone tablets (0.5, 2, or 4 mg/day) once a day for 2 weeks. They continued their conventional laxative. Their constipation and opiate withdrawal (OWS) were evaluated by the Bristol Stool Form Scale (stool consistency and frequency), Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire, Constipation Scoring System (CSS), and the Subjective Opiate Withdrawal Scale (SOWS) before starting treatment and at the end of the first and second weeks...
March 19, 2024: Irish Journal of Medical Science
https://read.qxmd.com/read/38449641/analysis-and-study-of-the-mechanism-of-narcotic-addiction-and-withdrawal
#9
JOURNAL ARTICLE
Yan Wang, Jiawei Ke, Shanshan Li, Qingling Kong, Mingyue Zhang, Mingming Li, Jing Gu, Meng Chi
Narcotic drugs refer to drugs that have anesthetic effects on the central nervous system, and they easily produce physical dependence and mental dependence and can be addictive due to continuous use, abuse or unreasonable use. In this paper, bioinformatics and data analysis and mining techniques were used to analyze the methylation differences in transcriptional and clinical data of narcotic addiction in public databases, to explore the mechanism of narcotic addiction, and to mine some norepinephrine drugs...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38377332/phenibut%C3%A2-an-illegal-food-supplement-with-psychotropic-effects-and-health-risks
#10
REVIEW
Udo Bonnet, Norbert Scherbaum, Andreas Schaper, Michael Soyka
BACKGROUND: Phenibut (β-phenyl-γ-aminobutyric acid) is an analog of the neurotransmitter gamma-aminobutyric acid (GABA). Like gabapentin and pregabalin, it inhibits α2-δ-subunits of voltage-dependent presynaptic calcium channels. The potential harm resulting from the use of these gabapentinoids is currently a matter of debate. METHODS: This review is based on pertinent publications retrieved by a selective literature search and on cases reported to the Giftinformationszentrum-Nord (GIZ-Nord), a poison information center at the University of Göttingen, Germany...
April 5, 2024: Deutsches Ärzteblatt International
https://read.qxmd.com/read/38309436/buprenorphine-induced-opioid-withdrawal-syndrome-relieved-by-adjunctive-magnesium-a-clinical-trial
#11
JOURNAL ARTICLE
Mohammad Moshiri, Bita Chaeideh, Mohsen Ebrahimi, Bita Dadpour, Alireza Ghodsi, Atoosa Haghighizadeh, Leila Etemad
INTRODUCTION: Precipitated opioid withdrawal syndrome (OWS) is a severe and intolerable situation that may occur by a pharmaceutical agent. Reactivation of inhibited N-methyl-d-aspartate (NMDA) receptor in person with prolonged opioid use can led to severe OWS. We conducted a double-blind, randomized clinical trial to assess the effect of magnesium sulfate (MGSO4 ) as an NMDA receptor antagonist on OWS. MATERIALS AND METHODS: The study randomly divided forty patients with precipitated OWS due to partial agonist (buprenorphine) use referred to the emergency unit of Toxicology Department of Mashhad University of Medical Sciences, Iran; into two groups...
February 2, 2024: J Subst Use Addict Treat
https://read.qxmd.com/read/38287506/characterizing-opioid-withdrawal-experiences-and-consequences-among-a-community-sample-of-people-who-use-opioids
#12
JOURNAL ARTICLE
Kelsey A Simpson, Maria Bolshakova, Matthew G Kirkpatrick, Jordan P Davis, Junhan Cho, Jessica Barrington-Trimis, Alex H Kral, Ricky N Bluthenthal
BACKGROUND: Opioid withdrawal symptoms are a highly salient and consequential health condition experienced by people who use opioids (PWUO). This study utilized qualitative interviews to explore opioid withdrawal experiences and consequences among PWUO in Los Angeles County, USA. METHODS: Semi-structured qualitative interviews were conducted with 22 PWUO (aged 27-63 years) between May 2021 and May 2022. Participants self-reported opioid and injection drug use in the last 30 days...
January 29, 2024: Substance Use & Misuse
https://read.qxmd.com/read/38283524/methadone-withdrawal-related-psychosis-in-a-patient-with-hormone-dependent-breast-cancer-a-case-report
#13
Mauro Pinho, Daniela O Martins, Francisco Coutinho
Methadone withdrawal usually presents as a classical opiate withdrawal syndrome, including symptoms such as restlessness, pupillary dilation, sweating, insomnia, irritability, sneezing, nausea, vomiting, and diarrhea. It rarely manifests as psychosis. Here, we discuss the case of a 43-year-old female with a history of long-term methadone use who presented with first-episode psychosis during methadone down-titration. She exhibited persecutory delusions and auditory hallucinations, unrelated to classical opiate withdrawal symptoms...
December 2023: Curēus
https://read.qxmd.com/read/38245698/brain-derived-neurotrophic-factor-serum-levels-as-a-candidate-biomarker-for-withdrawal-in-crack-heroin-dependence
#14
JOURNAL ARTICLE
Enam Alhagh Charkhat Gorgich, Mohammad Gol Rigi, Hamed Fanaei, Houman Parsaei, Abdolhakim Ghanbarzehi
BACKGROUND: Crack heroin is a novel opiate derivative with highly addictive properties and unfamiliar health consequences. It causes a variety of brain dysfunctions that are mediated by neurochemical alterations and abnormal neuroplasticity. Brain-derived neurotrophic factor (BDNF) is a widely recognized biological marker implicated in the neuropathology of substance use during substance use disorder and withdrawal. Its involvement can significantly contribute to the severity of withdrawal symptoms...
January 20, 2024: Substance Abuse Treatment, Prevention, and Policy
https://read.qxmd.com/read/38236644/targeting-mitochondrial-dynamics-of-morphine-responsive-dopaminergic-neurons-ameliorates-opiate-withdrawal
#15
JOURNAL ARTICLE
Changyou Jiang, Han Huang, Xiao Yang, Qiumin Le, Xing Liu, Lan Ma, Feifei Wang
Converging studies demonstrate the dysfunction of the dopaminergic neurons following chronic opioid administration. However, the therapeutic strategies targeting opioid-responsive dopaminergic ensembles that contribute to the development of opioid withdrawal remain to be elucidated. Here, we used the neuronal activity-dependent Tet-Off system to label dopaminergic ensembles in response to initial morphine exposure (Mor-Ens) in the ventral tegmental area (VTA). Fiber optic photometry recording and transcriptome analysis revealed downregulated spontaneous activity, dysregulated mitochondrial respiratory, ultrastructure, and oxidoreductase signal pathways after chronic morphine administration in these dopaminergic ensembles...
January 18, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38234935/rhabdomyolysis-in-the-context-of-designer-benzodiazepine-misuse
#16
Greg Noe, Kaushal Shah, Taylor Quattlebaum, Sahil Munjal
Designer benzodiazepines belong to a class of lab-created psychoactive compounds, with limited federal regulation, no toxicity testing, and reported high potency, leading to substantial overdose risk and harmful clinical syndromes. Benzodiazepine misuse has been previously documented to be associated with rhabdomyolysis, with elevated creatine kinase (CK) during and after acute episodes of intoxication. Here, we present a case of profound rhabdomyolysis and associated acute kidney injury (AKI) after acute designer benzodiazepine intoxication...
December 2023: Curēus
https://read.qxmd.com/read/38216357/evaluation-of-pre-hospital-cannabis-exposure-and-hospital-opioid-utilization-in-a-trauma-population-a-retrospective-cohort
#17
JOURNAL ARTICLE
Alexander J Chang, Ali F Mallat, Marc J Edwards, Joseph N Gabra, Michaelia D Cucci
PURPOSE: Cannabis utilization has increased over time for recreational and medical purposes due to its legalization or decriminalization. The effects of cannabis use on opioid utilization are not well understood. The primary objective was to evaluate the total opioid utilization, measured in morphine milligram equivalents (MME), in hospitalized trauma patients that tested positive for tetrahydrocannabinol (THC) on a urine drug screen (UDS). METHODS: This was a retrospective, cohort study in a level 1 trauma center between 10/17/17 and 12/31/19...
December 30, 2023: Injury
https://read.qxmd.com/read/38200140/pharmacokinetic-pharmacodynamic-analysis-of-drug-liking-blockade-by-buprenorphine-subcutaneous-depot-cam2038-in-participants-with-opioid-use-disorder
#18
JOURNAL ARTICLE
Sharon L Walsh, Sandra D Comer, Jurij Aguiar Zdovc, Céline Sarr, Marcus Björnsson, Kerstin Strandgården, Peter Hjelmström, Fredrik Tiberg
Buprenorphine is used to treat opioid use disorder (OUD). Weekly and monthly subcutaneous long-acting buprenorphine injections (CAM2038) provide more stable buprenorphine plasma levels and reduce the treatment burden, misuse, and diversion associated with sublingual transmucosal buprenorphine formulations. To characterize the pharmacokinetic/pharmacodynamic (PK/PD) relationship, a maximum inhibition (Imax ) model was developed relating CAM2038 buprenorphine plasma concentration to drug liking maximum effect (Emax ) visual analog scale (VAS; bipolar) score after intramuscular hydromorphone administration...
January 10, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38110799/implicit-racial-bias-in-evaluation-of-neonatal-opiate-withdrawal-syndrome
#19
JOURNAL ARTICLE
Katherine Nyman, Francesca Okolie, Natalie L Davis, Erin Hager, Dina El-Metwally
OBJECTIVE: To assess implicit bias by administrating the Modified Finnegan Score (MFS) for quantifying neonatal opiate withdrawal and to evaluate risk of decreased opiate treatment of Black versus White infants. STUDY DESIGN: Study participants were nurses recruited from a large tertiary care center who received three clinical vignettes portraying withdrawing infants and were randomized to receive an accompanying photo of either a Black or White infant. MFS results were compared for identical vignettes based on race of infant photo...
December 18, 2023: Journal of Racial and Ethnic Health Disparities
https://read.qxmd.com/read/38100521/barriers-and-best-practices-on-the-management-of-opioid-use-disorder
#20
REVIEW
Michelle Krichbaum, Daniela Fernandez, Devada Singh-Franco
Opioids refer to chemicals that agonize opioid receptors in the body resulting in analgesia and sometimes, euphoria. Opiates include morphine and codeine; semi-synthetic opioids include heroin, hydrocodone, oxycodone, and buprenorphine; and fully synthetic opioids include tramadol, fentanyl and methadone. In 2021, an estimated 5.6 million individuals met criteria for opioid use disorder. This article provides an overview of the pharmacology of heroin and non-prescription fentanyl (NPF) and its synthetic analogues, and summarizes the literature related to the management of opioid use disorder, overdose, and withdrawal...
December 15, 2023: Journal of Pain & Palliative Care Pharmacotherapy
keyword
keyword
161849
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.